Figure 2: (a) Percentage of patients with EBV DNA in blood in different groups.^aP, 0.09, glucocorticoids versus ASA;^bP, 0.008, AZA/6-MP versus ASA;^cP, 0.045, IFX versus ASA;^dP, 0.048, AZA/6-MP + IFX versus ASA (b) Percentage of patients with EBER-1 positivity in mucosal in different groups.^aP, 0.151, glucocorticoids versus ASA;^bP, 0.014, AZA/6-MP versus AZA;^cP, 0.083, IFX versus ASA.^dP, 0.025 AZA/6-MP + IFX versus ASA